MetaVia Secures $8.1 Million Funding to Advance Obesity Treatment DA-1726 Development

MetaVia Secures Funding to Advance Obesity Treatment Development

MetaVia Inc., a biotechnology company focusing on innovative solutions for cardiometabolic diseases, announces a pivotal step in its development journey with the pricing of an underwritten public offering aimed at raising approximately $8.1 million. Located in Cambridge, Massachusetts, MetaVia is primarily concentrating its efforts on DA-1726, a promising treatment for obesity. The offering comprises 2,613,544 shares of common stock alongside 3,920,316 Series C Warrants and 3,920,316 Series D Warrants, all set at a combined public offering price of $3.10 per share. This strategic move not only reflects the company's commitment to its clinical programs but also positions it for future growth in a competitive market focused on obesity and associated metabolic disorders.

The Series C and D Warrants included in the offering are particularly notable for their immediate exercisability at the same price of $3.10. The Series C Warrants have a five-year expiration, while the Series D Warrants are designed to expire in two years but become callable following favorable data from MetaVia's ongoing Phase 1b Part III clinical trial for DA-1726. Should all warrants be fully exercised, the company could garner an additional $24 million in gross proceeds. This financial influx is crucial as MetaVia aims to bolster its working capital and accelerate the clinical development of DA-1726. The net proceeds from this offering are expected to play a significant role in advancing the company’s research and development initiatives, particularly in the realm of obesity treatment.

MetaVia's public offering is being managed by Ladenburg Thalmann & Co. Inc., serving as the sole book-running manager. The transaction is anticipated to close around January 16, 2026, pending customary closing conditions. Additionally, the underwriters have a 45-day option to purchase more shares and warrants at the public offering price, allowing for potential further capital injection depending on market conditions. The securities were offered under a registration statement filed with the U.S. Securities and Exchange Commission (SEC), which adds a layer of compliance and credibility to MetaVia’s fundraising efforts.

As the healthcare landscape increasingly prioritizes obesity management, MetaVia's dedicated focus on DA-1726 positions it well within this dynamic sector. The promising treatment has the potential to address a growing public health crisis, and with the new funding, the company is poised to make significant strides in proving the efficacy and safety of its innovative solution. This offering marks a critical juncture in MetaVia’s journey as it endeavors to make a meaningful impact in the cardiometabolic space.